Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey

References (13)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analy- sis of population health data. Lancet 2006
2. [CrossRef] 2. Dinç G, Sözmen K, Gerçeklioğlu G, Arık H, Critchley J, Ünal B. Decreasing trends in cardiovascular mortality in Turkey between 1988 and 2008. BMC Public Health 2013
3. [CrossRef] 3. WHO. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization 2011. 4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013
4. e6-e245. [CrossRef] 5. Çakır B, Çalışkan Z, Ergun H, Erol C, Gümüşel B, Tokgözoğlu L, et al. PCV34 The Economic Cost of Acute Coronary Syndrome in Turkey. Value in Health 2012
5. A368. [CrossRef] 6. Ünal B, Sözmen K, Uçku R, Ergör G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anatol J Cardiol 2013
6. Onat A, Şenocak MS, Şurdum-Avcı G, Örnek E. Prevalence of coronary heart disease in Turkish adults. Int J Cardiol 1993
7. [CrossRef] 8. TURKSTAT. Turkish Health Survey 2010. Ankara: Turkish Statistical Institute 2012. 9. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. Turk Kardiyol Dern Ars 2012
8. [CrossRef] 10. Fak AS, Küçükoğlu MS, Fak NA, Demir M, Ağır AA, Demirtaş M, et al. Expert panel on cost analysis of atrial fibrillation. Anatol J Cardiol 2013
9. Taylor MJ, Scuffham PA, McCollam PL, Newby DE. Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 2007
10. [CrossRef] 12. MoH. General Directorate of Pharmaceuticals and Pharmacy Price List. 2013 [cited 11.05.2013]
11. Available from: http://www.iegm. gov.tr/Default.aspx?sayfa=fiyat_listesi. 13. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002
12. [CrossRef] 14. Moran JL, Solomon PJ, Peisach AR, Martin J. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract 2007
13. [CrossRef] 15. Ergin A, Eryol NK, Ünal S, Deliceo A, Topsakal R, Seyfel